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Abstract
Individuals who live to 85 and beyond without developing major age-related diseases may achieve this, in part, by lacking
disease susceptibility factors, or by possessing resistance factors that enhance their ability to avoid disease and prolong
lifespan. Healthy aging is a complex phenotype likely to be affected by both genetic and environmental factors. We
sequenced 24 candidate healthy aging genes in DNA samples from 47 healthy individuals aged eighty-five years or older
(the ‘oldest-old’), to characterize genetic variation that is present in this exceptional group. These healthy seniors were never
diagnosed with cancer, cardiovascular disease, pulmonary disease, diabetes, or Alzheimer disease. We re-sequenced all
exons, intron-exon boundaries and selected conserved non-coding sequences of candidate genes involved in aging-related
processes, including dietary restriction (PPARG, PPARGC1A, SIRT1, SIRT3, UCP2, UCP3), metabolism (IGF1R, APOB, SCD),
autophagy (BECN1, FRAP1), stem cell activation (NOTCH1, DLL1), tumor suppression (TP53, CDKN2A, ING1), DNA methylation
(TRDMT1, DNMT3A, DNMT3B) Progeria syndromes (LMNA, ZMPSTE24, KL) and stress response (CRYAB, HSPB2). We detected
935 variants, including 848 single nucleotide polymorphisms (SNPs) and 87 insertion or deletions; 41% (385) were not
recorded in dbSNP. This study is the first to present a comprehensive analysis of genetic variation in aging-related candidate
genes in healthy oldest-old. These variants and especially our novel polymorphisms are valuable resources to test for
genetic association in models of disease susceptibility or resistance. In addition, we propose an innovative tagSNP selection
strategy that combines variants identified through gene re-sequencing- and HapMap-derived SNPs.
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Introduction
Aging is a universal trait shared among most, if not all
organisms [1–3]. The rate and extent of aging, however, varies
substantially between species. The observed maximum human
lifespan of 122 years (Jeanne Calment, France) is surpassed only by
rougheye rockfish, red sea urchins, bowhead whales, and the
Galapagos land tortoise (all 150–200 years) [1,4–6]. A variety of
theories of why and how organisms age have been proposed,
including oxidative damage, telomere shortening, accumulation of
mutations and others (reviewed in [7]), but the contribution of
individual genes and variation within these genes is still under
investigation.
Molecular aging research has advanced substantially in recent
years through genomics and proteomics approaches, particularly
their application to understanding aging in various model
organisms. High-throughput screens for mutations that extend
lifespan in Saccharomyces cerevisiae, Caenorhabditis elegans, and
Drosophila melanogaster were successful in highlighting that deletion
or attenuation of single genes can result in substantial lifespan
extensions [8]. For example, the most intensively studied aging-
related gene in C. elegans is daf-2, an insulin/IGF receptor [9,10].
Reduction of daf-2 signaling in mutant worms leads to a doubling
of mean lifespan [11]. Mutations in the daf-2 homologs of
Drosophila and mice showed an 80% and 30% increase in lifespan,
respectively [12,13].
Human lifespan is also determined in part by genetic factors.
The heritability of human longevity is estimated as approximately
25% [14]. This estimate is also supported by a study of the entire
population of Iceland [15]. In addition, it was shown that siblings
of centenarians have a 4-fold greater probability of surviving to the
age of 91 [16]. A study of families with long-lived siblings localized
a longevity locus to a region on chromosome 4 [17,18].
In contrast to genetic loci related to extreme longevity,
mutations in single genes underlie several human premature aging
syndromes. Among these, Werner (OMIM: 277700), Bloom
(OMIM: 210900) and Hutchinson-Gilford Progeria (HGP;
OMIM: 176670) syndromes are segmental accelerated aging
syndromes. These severe conditions are caused by mutations in
DNA helicases in Werner and Bloom syndromes and in Lamin A
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impaired DNA repair/maintenance or nuclear instability, which
affect cell survival and tissue homeostasis [21]. This evidence
together argues for specific ‘aging genes’ that may represent key
components of pathways which when modulated results in pro- or
anti-aging effects. Variation within such genes may be a factor in
the inter-individual heterogeneity of human lifespan.
As a first step towards investigating the effects of genetic variation
in aging-related genes on human lifespan and health, we
characterized genetic variation in healthy oldest-old. To assess the
genetic variation in a selection of aging-related candidate genes we
have re-sequenced 24 genes in healthy seniors 85 years old or older.
Candidate genes were selected either through gene expression
analysis of long-lived C. elegans daf-2 mutants [10] or literature
reports. Genes previously identified as differentially expressed in
long-lived daf-2 mutants compared to wild type worms included
genes involved in metabolism (IGF1R (GeneID: 3480), SCD
(GeneID: 6319), APOB (GeneID: 338)) and stress response (CRYAB
(GeneID: 1410), HSPB2 (GeneID: 3316)). Response to dietary
restriction (DR) is suggested to be an evolutionary conserved
mechanism that enhances survival in adverse environmental
condition but also extends lifespan [22]. Key genes of dietary
restriction-mediated lifespan extension have been identified in
animal studies and include sirtuins (SIRT1 (GeneID: 23411), SIRT3
(GeneID: 23410)), uncoupling proteins (UCP2 (GeneID: 7351),
UCP3 (GeneID: 7352)), PPARG (GeneID: 5468) and PPARGC1A
(GeneID: 10891). Additional candidate gene categories chosen,
included autophagy (BECN1 (GeneID: 8678), FRAP1 (GeneID:
2475)), tumor suppression (TP53 (GeneID: 7157), CDKN2A
(GeneID: 1029), ING1 (GeneID: 601566)), DNA methylation
(TRDMT1 (GeneID: 1787), DNMT3A (GeneID: 1788), DNMT3B
(GeneID: 1789)), stem cell activation (NOTCH1 (GeneID: 4851),
DLL1 (GeneID: 28514)), and Progeria syndromes (LMNA (GeneID:
4000), ZMPSTE24 (GeneID: 10269), KL (GeneID: 9365)). Refer-
ences for all candidate genes are provided in Table 1.
Genes from these various biological pathways are functionally
interconnected; for instance, DR affects most, if not all, of the
other categories of genes. DR reduces cancer risk in model
organisms [23], induces autophagy [24], changes DNA methyla-
tion [25] and even ameliorates loss of stem cell function with age
[26]. Other examples of inter-pathway connections are DNA
methylation and tumor suppression [27] as well as Progeria
syndromes and stem cell activity [21].
In addition to characterizing the extent of genetic variation in
these aging-related candidate genes, our second goal was to
establish tagSNP sets that incorporated both genetic information
from a reference population, as well as specific variants discovered
in our exceptional healthy oldest-old. This combined approach
benefits from valuable information generated by the HapMap
project [28] as well as incorporating rare alleles, which in
aggregate may have major contributions to susceptibility or
resistance to disease [29].
Table 1. Candidate genes, relevance to aging and biological function.
Relevance to Aging Gene Name (H. sapiens/C. elegans) Biological Function Reference
Gene Expression Study IGF1R/daf-2 growth factor/IGF-1 signaling [10]
(C. elegans daf-2) SCD/fat - gene family lipid metabolism, Stearoyl-CoA desaturase
APOB/vit - gene family lipid metabolism, low density lipoproteins
CRYAB/hsp-12 and hsp-16 small heat shock protein
HSPB2/hsp-25 small heat shock protein
Dietary Restriction SIRT1 NAD-depended deacetylase [48]
SIRT3 mitochondrial respiration, ROS production [49]
UCP2 uncoupling protein, ROS production [50]
UCP3 uncoupling protein, ROS production [51]
PPARG key regulator of white adipose tissue [52]
PPARGC1A mitochondrial biogenesis [53]
Autophagy FRAP1 environmental sensor, general metabolism [54]
BECN1 key regulator of autophagy [55]
Stem Cell Activation NOTCH1 muscle satellite cell activation [56]
DLL1 ligand of NOTCH1
Progeria Syndrome LMNA mutated in HGPS [19]
ZMPSTE24 posttranslationally modifies LMNA protein [57]
KL preamature aging in mouse [58]
Tumor Suppression TP53 tumor suppression, cell cycle control [59]
ING1 tumor suppression, apoptosis [60]
CDKN2A tumor suppression, cellular senescence [61]
DNA Methylation TRDMT1 DNA/RNA methytransferase [62]
DNMT3A de novo DNA methyltransferase [63]
DNMT3B de novo DNA methyltransferase [27]
ROS - reactive oxygen species (free radicals)
HGPS - Hutchinson-Gilford Progeria Syndrome
doi:10.1371/journal.pone.0006641.t001
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‘healthy aging’ genes we have re-sequenced the exons, intron-exon
boundaries, 1500 bp upstream regions and conserved sequences in
47 healthy oldest-old. We present a catalogue of genetic variation in
aging-related genes and highlight the value of gene re-sequencing
for identifying SNPs for testing in genetic association studies.
Results
Variant Discovery by Gene Re-sequencing
Table 1 summarizes the 24 candidate healthy aging genes,
their biological function, and relevance to aging or longevity. For
variant detection, we used blood DNA from 47 healthy oldest-old
(mean age 89 years, median age 88 years). These individuals have
never been diagnosed with cancer, cardiovascular disease,
diabetes, Alzheimer disease or major pulmonary disease.
For each candidate gene, we bi-directionally re-sequenced all
exons (including exons of known alternative transcripts), 59 and 39
untranslated regions (UTRs), all intron-exon junctions, 1500 bp
upstream (including the core promoter) and selected conserved
non-coding sequences (CNS). Our criteria for a CNS was a
minimum of 70% conservation over at least 100 bp. Table 2
summarizes amplicon sequencing and variant discovery. Per
individual, we sequenced 716 amplicons and ,360 Kb of DNA.
Overall, we generated and analyzed ,35 million high quality
(Phred 20) DNA bases. We detected 935 variants (on average one
every 400 bp), of which 550 (59%) are represented in dbSNP
(build 126) and 385 (41%) were novel. 87 (9%) are insertions or
deletions. The average minor allele frequency (MAF) is 15%.
There is a marked difference in the average MAF of markers
represented in dbSNP and ones that are not, 21% and 6%
respectively. 72% (398/550) of variants that are in dbSNP have a
MAF of $5%, whereas only 22% (84/385) of novel variants have
a MAF of 5% or greater. Despite a MAF of 19% for all insertion/
deletion variants, only 30% (26/87) have an entry in dbSNP.
BECN1 and DNMT3A show the lowest degree of variation (1.1
variant/1000 bps), whereas SIRT3 and TRDMT1 have the
highest; 5.5 and 5.1 variants/1000 bps, respectively. Supple-
mental online Table S1 lists the 935 variants discovered
through candidate gene re-sequencing, their genomic location,
flanking sequences, dbSNP rs number, nucleotide difference,
codon/amino acid difference, and MAF.
Table 3 summarizes the locations of these genetic variants
within each gene. The highest numbers of variants are within
introns (353). The second most abundant group of variants is
found in CNS (317). These include highly conserved non-coding
sequences that were chosen through phylogenetic footprinting
(within615 kb of the candidate genes), and 1500 bp upstream of
the transcriptional start sites. Furthermore, we found 128 variants
in 59 and 39 UTRs and seven within 6 bp of exon-intron junctions
Table 2. Amplicon sequencing and variant discovery.
Gene Name
Number of Amplicons
(Exon, CNS
a) Kb Sequenced
Number of
Variants
Variants per
1000 bp
Number of Novel
Variants (%)
b
Insertion or
Deletion
IGF1R 52 (29, 23) 20 68 3.4 33 (49) 9
SCD 26 (20, 6) 12 30 2.5 12 (40) 6
APOB 75 (56, 19) 33 57 1.7 21 (37) 1
CRYAB 10 (3, 7) 4 8 1.8 3 (38) 0
HSPB2 5 (4, 1) 2 4 1.8 1 (25) 0
SIRT1 21 (18, 3) 11 30 2.7 17 (57) 7
SIRT3 14 (10, 4) 7 40 5.5 13 (33) 3
UCP2 14 (8, 6) 7 19 2.7 12 (63) 3
UCP3 18 (10, 8) 10 38 3.9 17 (45) 4
PPARG 21 (11, 10) 12 33 2.8 11 (33) 3
PPARGC1A 36 (23, 13) 20 50 2.6 28 (56) 6
FRAP1 74 (64, 10) 39 65 1.7 22 (34) 2
BECN1 19 (10, 9) 9 10 1.1 8 (80) 3
NOTCH1 50 (37, 13) 28 117 4.1 46 (39) 4
DLL1 22 (12, 10) 11 28 2.5 13 (46) 1
LMNA 26 (18, 8) 13 30 2.2 9 (30) 4
ZMPSTE24 22 (18, 4) 11 15 1.3 4 (27) 0
KL 32 (22, 10) 17 41 2.5 14 (34) 4
TP53 26 (16, 10) 7 36 4.9 13 (36) 3
ING1 22 (19, 3) 11 26 2.3 13 (50) 7
CDKN2A 16 (14, 2) 11 15 1.4 8 (53) 0
TRDMT1 29 (25, 4) 16 80 5.1 26 (33) 9
DNMT3A 49 (38, 11) 28 31 1.1 21 (68) 3
DNMT3B 37 (30, 7) 20 64 3.2 20 (31) 5
Total 716 (515, 201) 360 935 avg. 2.7 385 (41%) 87 (9%)
aconserved non-coding sequences (CNS) and 1500 bp upstream.
bdbSNP (build 126), Kb - kilobase pairs.
doi:10.1371/journal.pone.0006641.t002
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genes, we found 54 non-synonymous and 76 synonymous variants.
All of these are SNPs, with one exception; a Leu-Leu-Ala deletion
in exon 1 of APOB. The 80 coding variants that are represented in
dbSNP are, on average, more common (average MAF 19%) than
our 50 novel coding SNPs (average MAF 1.6%).
TagSNP Selection: Combining Public HapMap and Private
Re-sequencing Variants
To minimize the number of variants that have to be genotyped
in association studies, we devised an innovative tagSNP selection
protocol outlined in Figure 1. This protocol is designed to
incorporate both common and less common variants. Because
variants discovered in healthy oldest-old represent potential
healthy aging alleles, we include SNPs with MAF $2% that were
found in re-sequencing. This was equivalent to including variants
that had been observed at least twice, but excluded ‘singletons’
that had been observed only once. To pick tagSNPs representing
SNPs found by re-sequencing, we set a high threshold of r
2=1.0,
since we did not want to leave out any SNPs from this unique
source. To cover genetic variation in the introns and gene
proximity we also included HapMap SNPs for the European
ancestry population (CEU) chosen based on genomic regions of
candidate genes610 Kb. MAF $5% and r
2=0.8 were used to
choose representative tagSNPs from among these known SNPs.
To apply our SNP selection method, first a set of 179 SNPs
found in both our re-sequencing SNP set and in HapMap was
identified, and 120 tagSNPs were picked to represent them with
MAF $2% and r
2=1.0 in the re-sequencing set. These SNPs
were then prioritized in the selection of additional tagSNPs to
represent the set of HapMap SNPs in the region that had
minimum MAF=5%, at r
2=0.8. They were also prioritized in the
selection of additional tagSNPs to represent the other re-
sequencing SNPs, with MAF $2%, at r
2=1.0.
Table 4 summarizes the results of tagSNP selection using this
method, including the number of variants available per gene and
the resulting number of tagSNPs. 340 tagSNPs (32%) represent
1045 HapMap SNPs, whereas 462 tagSNPs (67%) represent 684
gene re-sequencing variants. Our approach selected 682 tagSNPs
that represent 1550 variants, representing a 56% reduction of
variants that need to be genotyped to represent the entire set. The
majority of tagSNPs are actual SNPs, whereas, exclusively in the
re-sequencing set, a few ‘tagSNPs’ refer to insertions or deletions.
Of note is the low degree of overlap between HapMap and gene
re-sequencing variants. For all 24 candidate genes analyzed, only
12% of variants (179/1550) are shared between available
HapMap SNPs and sequencing data generated from our healthy
Table 3. Genomic location of variants.
Gene Name Non-Synonymous Synonymous UTR
a Flanking, CNS
b Splice Site
c Intron TOTAL
IGF1R 2 8 10 35 1 12 68
SCD 1 0 14 10 0 5 30
APOB 19 8 2 24 0 4 57
CRYAB 11 0 3 1 2 8
HSPB2 11 0 2 0 0 4
SIRT1 22 5 7 1 1 3 3 0
SIRT3 42 6 8 1 1 9 4 0
UCP2 11 8 3 0 6 1 9
UCP3 2 2 5 18 0 11 38
PPARG 11 0 9 0 2 2 3 3
PPARGC1A 3 3 12 25 0 7 50
FRAP1 0 6 5 14 0 40 65
BECN1 00 1 5 0 4 1 0
NOTCH1 5 13 9 13 1 76 117
DLL1 13 3 1 4 0 7 2 8
LMNA 0 5 3 12 0 10 30
ZMPSTE24 01 2 4 0 8 1 5
KL 3 6 3 18 0 11 41
TP53 1 3 3 19 0 10 36
ING1 11 1 3 8 0 3 2 6
CDKN2A 30 4 6 0 2 1 5
TRDMT1 2 4 12 37 1 24 80
DNMT3A 0 2 2 10 0 17 31
DNMT3B 1 3 6 13 1 40 64
Total 54 76 128 317 7 353 935
aUTR - 59 and 39 untranslated regions.
bFlanking, CNS includes 1500 bp upstream of genes and 39 gene flanking sequence. CNS=conserved non-coding sequences.
cwithin 6 bp from the exon-intron junction.
doi:10.1371/journal.pone.0006641.t003
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cannot be inferred in the other set, HapMap and candidate gene
re-sequencing variants have to be treated, for LD-based tagSNP
selection, as different data sets. Prioritizing variants found in both
sets in our tagSNP selection method, however, increased the
number of overlapping SNPs in the tagSNP set to 18% (120/682)
(Figure 1).
We conclude from this analysis that if only SNPs available
through the HapMap project had been chosen to represent the
regions sequenced in our candidate genes, we would only have
represented 26% of the variants (179/684) that are actually
present in our study population (Figure 1 and Table 4).
Subsequently, tagSNPs chosen using this combined method were
genotyped in 493 healthy oldest old and 439 random individuals
aged 40–50, using the Illumina GoldenGate method (data not
shown). Only 7 out of 245 (2.4%) private re-sequencing tagSNPs
were represented by 297 HapMap tagSNPs at r
2=0.8.
Discussion
Besides genes that have been shown to affect lifespan in animal
models, a limited number of genetic variants have been reported
to be associated with long life in humans. These studies mainly
evaluated genetic variation linked to extreme human life spans
(e.g. centenarians) without focusing specifically on health. Such
genes include APOE (GeneID: 348) [30,31], CETP (GeneID: 1071)
[32], Interleukin 6 (GeneID: 3569) [33,34], Interleukin 10
(GeneID: 3586) [35,36], PON1 (GeneID: 5444) [37], FOXO3A
(GeneID: 2309) [38,39] and SIRT3 [40]. Controversy exists
regarding the contribution of these and other gene variants to
aging and longevity, because replication studies in different
populations, as for replication studies in complex diseases, more
often than not fail to confirm the initially reported associations.
For instance, the common polymorphism I405V in CETP that was
associated with longevity in Ashkenazi Jewish centenarians was not
confirmed in an Italian replication study [41]. A comprehensive
summary of genetic variants that have been tested for association
with human aging/longevity can be found at http://genomics.
senescence.info/genes. Almost exclusively, these studies tested
single variants in candidate genes without surveying the whole
gene in a more comprehensive manner.
For a limited number of genes, including APOE, FOXO3A,
and PON1, association of specific variants with aging/longevity
has already been established [30,31,37–39]. These associations,
however, only account for a fraction of the genetic contribution to
aging and longevity. Our candidate gene choice reflects the need
to assess genetic variation in a broader spectrum of genes that
affect aging-related biological mechanisms and pathways, partic-
ularly in animal models. Although it is plausible that additional
‘causal’ variants exist in these documented aging-associated genes,
we focused on an independent set of genes to generate genetic
variation data for use in association studies.
Large-scale sequencing efforts will be necessary to construct a
complete picture of genetic contributions to aging and other
complex phenotypes. Although advances in DNA sequencing
technologies will ultimately provide sequence information of all
exons and whole genomes, it will take time until comprehensive
genomic information will be available for large cohorts of long-
lived individuals. Until then, targeted re-sequencing studies, as
presented here, will add value to genetic epidemiology studies.
The common variant common disease hypothesis proposes that
genetic susceptibility to common conditions and diseases like
hypertension and diabetes is largely due to alleles that have
moderate frequency in the population [42]. The ‘rare variant
hypothesis’ in contrast, argues that a significant proportion of
inherited susceptibility to relatively common chronic diseases is
due to the cumulative effects of many low frequency dominantly
and independently acting variants of a variety of different genes,
and that each of these variants confers a moderate increase in
relative disease risk [29]. For many diseases, it is not yet clear
which of these hypotheses, or both, will be applicable. Current
genome-wide association studies (GWAS) are capable of testing for
association with many, even a million, relatively common SNPs,
but do not comprehensively test for association with rare variants.
Current studies may therefore neglect the effects of this important
set of genetic variants [29]. Healthy aging is an uncommon
Figure 1. TagSNP selection strategy. HapMap genotypes for European individuals were obtained from the HapMap database. For each
candidate gene, SNPs within the gene region610 Kb were included. A MAF $5% and an r
2=0.8 were used for tagSNPs selection using Haploview.
Variants with a MAF $2% were analyzed in the gene re-sequencing set, with r
2=1.0. Using a two-stage approach, we selected 682 tagSNPs that
represent 1550 non-redundant variants from gene re-sequencing and HapMap data sets. tagSNPs (120) representing the 179 shared variants found in
both data sets were determined in the gene re-sequencing set. CNS=conserved non-coding sequences.
doi:10.1371/journal.pone.0006641.g001
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to achieve our definition of healthy aging). Rare variants, with
more substantial genetic effects, are generally more important in
rare disorders than common ones [29]. We reason that multiple
rare variants could in theory play a role in the healthy aging
phenotype.
We have re-sequenced aging-related candidate genes to
systematically detect common and rare variants that potentially
contribute to healthy aging and disease-resistance. This set of 935
variants (summarized in supplemental online Table S1) will
provide a valuable resource for the bio-gerontological as well as
the biomedical communities, the more so because rare variants
and particularly insertions and deletions are underrepresented in
dbSNP and HapMap [43]. Some rare missense variants or
variants in the promoter or other gene regulatory regions may
have effects on gene expression [29]. In our study, 201 (of 716)
amplicons covered conserved nucleotide sequence regions. Vari-
ants in these regions (including UTRs) accounted for 48% of all
variants (445/935), providing a substantial data set for functional
studies of these genes.
Current genotyping studies, regardless of phenotype, typically
rely on common ethnicity-specific HapMap tagSNPs to represent
common variation in targeted regions (candidate genes) or within
whole genomes (GWAS). We reason that healthy aging and
longevity are unlikely to be due solely to the presence of a small
number of common variants. This desirable phenotype may in
part be due to absence of specific disease-causing alleles, as well as
presence of favorable combinations of other alleles. For this
reason, limiting association studies of healthy aging or longevity to
testing common SNPs may be unsuccessful, or at best incompletely
successful. Ultimately, more sophisticated analyses enabled by full
genome sequencing will allow the assessment of both common and
rare variants. In the meantime, a relatively cost effective approach
for candidate gene-based analyses is to perform SNP discovery in
cases with the phenotype of interest, for later comparison to
appropriate controls. In this study, we not only establish a catalog
of genetic variation in genes relevant to aging in healthy oldest old,
we also use this data to ask whether current public SNP resources
can represent this deeper variation. We find that, while HapMap
tagSNPs are known to be very useful for representing common
Table 4. tagSNP selection; HapMap versus candidate gene re-sequencing.
Gene Name Number of variants Number of tagSNPs
Sequencing
Variants
a
Shared
Variants
b
HapMap
Variants
c
Total non-
redundant
Variants
Shared
(%)
Sequencing
tagSNPs
d
Shared
tagSNPs
HapMap
tagSNPs
e
Total non-
redundant
tagSNPs
Shared
(%)
IGF1R 48 2 122 168 1 44 2 36 78 3
SCD 2 5 7 3 14 91 4 1 4 61 22 03 0
APOB 37 11 38 64 17 31 10 16 37 27
CRYAB/HSPB2
# 1 2 481 6 2 5 1 03 31 0 3 0
SIRT1 1 6 5 2 73 81 3 1 0 35 1 22 5
SIRT3 32 11 37 58 19 16 5 13 24 21
UCP2 1 3 4 1 72 61 5 7 26 1 11 8
UCP3 2 9 7 2 34 51 6 1 8 68 2 03 0
PPARG 23 9 117 131 7 19 6 24 37 16
PPARGC1A 30 12 112 130 9 24 11 51 64 17
FRAP1 4 5 9 4 37 91 1 1 3 57 1 53 3
BECN1 11 0 2 13 0 11 0 2 13 0
NOTCH1 93 19 38 112 17 75 18 34 91 20
DLL1 1 7 3 1 42 81 1 1 3 31 32 31 3
LMNA 2 3 6 1 83 51 7 1 1 36 1 42 1
ZMPSTE24 1 1 7 2 32 72 6 9 61 01 34 6
KL 32 13 101 120 11 22 5 22 39 13
TP53 2 2 1 1 43 53 1 5 18 2 25
ING1 1 7 3 1 32 71 1 1 4 13 1 66
CDKN2A 15 2 23 36 6 14 2 9 21 10
TRDMT1 64 24 124 164 15 29 9 12 32 28
DNMT3A 1 8 4 5 16 56 1 5 32 33 59
DNMT3B 51 16 49 84 19 28 10 17 35 29
Total 684 179 1045 1550 12% 462 120 340 682 18%
aMAF $2%.
bvariants observed in the re-sequencing and HapMap data sets.
cMAF $5%.
dr2=1.0.
er2=0.8.
#CRYAB/HSPB2 are adjacent to each other on chromosome 11 and were analyzed together.
doi:10.1371/journal.pone.0006641.t004
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studies of uncommon phenotypes of interest like healthy aging.
The variants reported here, especially our novel polymorphisms,
can be taken forward by the aging research community, as well as
byinvestigatorswho studythesegeneswith regardtodiseases,totest
for genetic association in relevant populations. In addition, our data
informs the study designs of the future, by helping to justify larger
scale next-generation sequencing for enabling more comprehensive
comparisons of groups of cases and controls.
Our approach aims to provide deeper coverage and enable
analysis of both common and rare variants, without unnecessarily
increasing genotyping costs and effort. It involves selecting a
minimal set of tagSNPs that represent two or more independent
sets of SNPs from each candidate gene. A final tagSNP list
generated with our combined selection method is limited to the
ethnicity it was generated for. TagSNP selection for other
ethnicities would require separate analyses, ideally using HapMap
data from that population and re-sequencing data from the same
population. Transferability in between study populations of the
same ethnicity (e.g. oldest-old, centenarians, or super-centenari-
ans) is feasible but would solely depend on the presence of the
private re-sequencing variants amongst these populations.
Our tagSNP selection strategy uses Tagger, a well-documented
tool for the selection and evaluation of tagSNPs from genotype
data [44]. The main value of our tagSNP selection process is based
on the fact that future targeted genotyping projects, as opposed to
whole genome SNP scans, will combine variation information
from public (HapMap) and private sources potentially derived
from next-generation sequencing of individuals with phenotypes of
interest. Our study design is capable of finding effects due to rare
variants if subsequently tested in a large enough case/control
resource. The strategy in which regional re-sequencing is done
only after a region of interest is identified through a HapMap-
based strategy, will generally not detect the effects of rare variants.
Our tagSNP analysis showed that only 19% (179/935, Table 2
and Figure 1) of variants seen in the re-sequencing set are also
represented in HapMap. This discrepancy is based on the facts
that HapMap mainly supports common variants (MAF $5%) and
that those variants were chosen to distribute relatively uniformly
across genomic regions. In our re-sequencing data, 28% (264/935)
of all variants are singletons, emphasizing the abundance of
private variants within individuals. Contributions of these rare
variants to individual disease risk cannot be evaluated solely using
HapMap tagSNPs.
In genotype data for the combined tagSNP set, generated in 493
healthy oldest old and 439 random individuals aged 40–50, only 7
out of 245 (2.4%) private re-sequencing tagSNPs were represented
by 297 HapMap tagSNPs at r
2=0.8. This shows that HapMap
tagSNPs generally do not adequately represent, private re-
sequencing SNPs. This analysis highlights a major challenge for
genetic association studies. Using only HapMap SNPs, effects due
to uncommon variants would often be missed.
Healthy oldest-old rather than centenarians or healthy cente-
narians have been chosen for this study based on demographic
data, which suggests that in western countries less than 36% of
individuals live up to 85 years and that only one third of these will
do so in good health (,12% overall) [45]. Hence, healthy oldest-
old are uncommon in the population, but not as rare as
centenarians (1 per 3300 people in the US). We have collected
lifestyle, education and other information for the entire collection
of healthy oldest-old (550 individuals, of which the 47 individuals
sequenced are a subset) and also for 550 controls for use in future
association study, to be able to control for major lifestyle and
socio-economic factors in future association studies.
Our study is the first to present a comprehensive analysis of
genetic variation in aging-related candidate genes in the healthy
oldest-old. Genetic association studies of aging and longevity to
date have relied mainly on known variants or on common variants
from dbSNP and HapMap as detailed genetic variation maps of
aging-related genes in individuals of advanced age are not yet
available. Testing these variants in case-control studies or families
with a history of long-lived individuals can greatly assist the search
for genetic factors that contribute to successful and healthy aging
and longevity.
Materials and Methods
This study was approved by the joint Clinical Research Ethics
Board of the British Columbia Cancer Agency and the University
of British Columbia. All subjects gave written informed consent.
Study Participants
Subjects were recruited between January 2004 and August 2007
in the Greater Vancouver Regional District in British Columbia,
Canada. Participants were 85 years or older at the time of
recruitment and reported that they had never been diagnosed with
cancer, cardiovascular disease, diabetes, major pulmonary disease,
or Alzheimer disease. We conducted detailed questionnaires about
their personal and family medical history, medication and
supplements. We also took blood pressure measurements, assessed
their body mass index, smoking habits, alcohol consumption,
physical exercise, stress history, and educational and occupational
background. Standard geriatric tests to assess memory, cognition,
psychological status, and mobility of study subjects were
performed. These included the Folstein Mini Mental Status Exam
(MMSE), the Instrumental Activities of Daily Living Scale (IADL),
the Geriatric Depression Scale (GDS), and the Timed Get Up and
Go Test (TUG). Out of a pool of 300 subjects recruited by June
2005, we selected 47, who scored very high on the geriatric tests,
for candidate gene re-sequencing. Average scores for these
geriatric tests were: MMSE=28.5, IADL=22.3, GDS=1.1,
and TUG=11.3. Forty-six of these sequenced subjects have all
four grandparents of European ancestry; one is Southeast Asian.
Genomic DNA was extracted from peripheral blood samples using
the PureGene DNA isolation kit (Gentra Systems, MN) according
to the manufacturer’s instructions.
Conserved Nucleotide Sequences
Conserved nucleotide sequences (CNS) were identified by
phylogenetic footprinting using the VISTA browser (http://
pipeline.lbl.gov/cgi-bin/gateway2). CNS regions were selected in
introns and within 15 kb up- and downstream of candidate genes.
Genomic sequences of at least four organisms were aligned with
the human reference genome. Available genomic sequences
included chimpanzee, baboon, rhesus monkey, cow, dog, horse,
opossum, mouse, rat, rabbit, chicken, frog, zebrafish, and fugu.
Alignments with organisms that are in evolutionary terms either
extremely close (chimpanzee, baboon) or not (fugu, zebrafish) were
usually less informative. The selection criterion for CNS was a
minimum of 70% conservation over at least 100 bp.
Bidirectional Sequencing
PCR primers (see Supplemental online Table S2) were
designed for 716 genomic regions, including 515 exons and 201
putative gene regulatory regions (CNS), which include 1500 bp
upstream of the transcriptional start site of each gene. A total of
,360 Kb of DNA sequence was PCR amplified per individual.
Coding exons were amplified using primers designed in the intronic
Genetics of Healthy Aging
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all intron/exon junctions. The average amplicon size was 513 bp,
the maximum 700 bp. Exons and CNS regions that span more that
700 bp were amplified in overlapping segments. Primers for 14
genes were designed manually for DNA sequences retrieved from
the UCSC genome browser (hg18) using the program Primer3 [46].
Primers for the remainder were downloaded from the NCBI probes
webpage (http://www.ncbi.nlm.nih.gov/sites/entrez?db=probe)
and further supplemented with primers designed in-house for
regions not covered. Forward and reverse primers incorporated the
-21M13F (TGTAAAACGACGGCCAGT) or M13R (CAG-
GAAACAGCTATGAC) extensions, respectively, at their 59 ends.
PCR, sequencing reactions and sequence analysis procedures were
carried out as described previously [47]. Briefly, PCR reactions
were optimized for each individual primer pair using genomic test
DNA and a temperature gradient (48–65uC). Standard PCR
conditions were 15 s annealing time, 30 s extension time, and 35
cycles. A standard 10 ul (optimization) or 20 ul (sample) PCR
reaction mix contained 1 mM MgSO4, 0.2 mM dNTPs, 0.5 uM of
each primer, 0.0125 units Platinum Pfx Polymerase, 16Enhancer
solution, 16Pfxamplification buffer (allfrom Invitrogen,CA,USA)
and 10 ng genomic DNA. Primer pairs showing no product or high
background amplification were re-tested at slightly different
conditions (annealing time: 5 s–1 min; extension time: 10 s–1 min)
or re-designed if necessary (,5% of primers). The majority of
primers worked at 60uC( 63uC). All PCR products, optimizations as
well as sample PCRs, were checked on 2% agarose gels (SeaKem
LE, Cambrex, ME, USA). For cycle sequencing, we used Big Dye
Terminator Mix v3.1 (Applied Biosystems, Foster City, CA) at
0.33 ml of mix per reaction in a total volume of 4 mlw i t h5 0c y c l e so f
amplification and ABI 3730 capillary sequencers. DNA sequence for
14 out of 24 genes was analyzed with Phred/Phrap/polyphred-
5.02/polyphred-7/Consed 14 as described [47]. The remainder of
genes was analyzed using Mutation Surveyor (Softgenetics, PA,
USA).5geneswereanalyzedwithbothsoftwaretoolstodemonstrate
no appreciable difference in the detection of sequence variants. In
total we generated and analyzed 34.8 million base pairs. All variants
were verified by at least two researchers.
TagSNP selection
For all 24 candidate genes we inferred tagSNPs from our
sequenced variants as well as from data available through the
HapMap project. European variants for our candidate gene regions
(610 Kb) and a MAF $5% were obtained from the HapMap
website (www.hapmap.org). For the gene re-sequencing data, we
generally considered variants (SNPs and insertion/deletions) with
MAF $2%; the 684 re-sequencing variants included 30 variants
with a MAF ,2%. The Tagger tagSNP selection algorithm
implemented in Haploview (version 4.1, http://www.broad.mit.
edu/node/443) was used for selecting tagSNPs. 3% of singleton
variants (MAF=1.1%) are exclusively observed in the Southeast
Asian sample as opposed to over 30% in the European samples.
These specific Southeast Asian variants are included in our report
but were excluded from the tagSNP analysis.
Supporting Information
Table S1 Variants discovered by candidate gene sequencing
Found at: doi:10.1371/journal.pone.0006641.s001 (0.25 MB
XLS)
Table S2 PCR primer information
Found at: doi:10.1371/journal.pone.0006641.s002 (0.22 MB
XLS)
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